{"transactions":[{"id":1105149,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78282,"kind":"person","name":"Stultz Katherine V","position":1,"cik":"0001864500","reported_name":"Stultz Katherine V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:16.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.95,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-25-017824","document":"form4-06202025_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864500/000141588925017824/form4-06202025_040603.xml","form_type":"4"}},{"id":1105148,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78282,"kind":"person","name":"Stultz Katherine V","position":1,"cik":"0001864500","reported_name":"Stultz Katherine V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:16.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.48,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":7079},"source":{"system":"sec-edgar","filing":"0001415889-25-017824","document":"form4-06202025_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864500/000141588925017824/form4-06202025_040603.xml","form_type":"4"}},{"id":1105147,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78282,"kind":"person","name":"Stultz Katherine V","position":1,"cik":"0001864500","reported_name":"Stultz Katherine V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:16.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":68000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.29,"expiration_date":"2033-04-09","underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001415889-25-017824","document":"form4-06202025_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864500/000141588925017824/form4-06202025_040603.xml","form_type":"4"}},{"id":1468814,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78282,"kind":"person","name":"Stultz Katherine V","position":1,"cik":"0001864500","reported_name":"Stultz Katherine V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-26T16:35:47.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34000,"derivative":{"exercise_price":0.95,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-24-018237","document":"form4-06262024_080642.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864500/000141588924018237/form4-06262024_080642.xml","form_type":"4"}},{"id":1844378,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78282,"kind":"person","name":"Stultz Katherine V","position":1,"cik":"0001864500","reported_name":"Stultz Katherine V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:14:02.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":7079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":7079,"derivative":{"exercise_price":1.48,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":7079},"source":{"system":"sec-edgar","filing":"0001209191-23-039693","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864500/000120919123039693/doc4.xml","form_type":"4"}},{"id":1921859,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78282,"kind":"person","name":"Stultz Katherine V","position":1,"cik":"0001864500","reported_name":"Stultz Katherine V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-04-11T16:40:51.000Z","date":"2023-04-10","kind":"grant","planned":false,"acquired":true,"shares":68000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in three equal annual installments following the date of grant."}],"balance_after":68000,"derivative":{"exercise_price":1.29,"expiration_date":"2033-04-09","underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001209191-23-024020","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864500/000120919123024020/doc4.xml","form_type":"4"}},{"id":2648090,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":78282,"kind":"person","name":"Stultz Katherine V","position":1,"cik":"0001864500","reported_name":"Stultz Katherine V","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Series B Preferred Stock","published_at":"2021-07-01T19:01:02.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":19763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8126},"source":{"system":"sec-edgar","filing":"0000899243-21-027015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1864500/000089924321027015/doc4.xml","form_type":"4"}},{"id":2648089,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":78282,"kind":"person","name":"Stultz Katherine V","position":1,"cik":"0001864500","reported_name":"Stultz Katherine V","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T19:01:02.000Z","date":"2021-03-17","kind":"grant","acquired":true,"shares":89934,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted subject to the achievement by the Company of performance vesting criteria. On June 29, 2021 the performance vesting criteria was met such that the option became reportable. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":89934,"derivative":{"exercise_price":6.11,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":89934},"source":{"system":"sec-edgar","filing":"0000899243-21-027015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1864500/000089924321027015/doc4.xml","form_type":"4"}},{"id":2648088,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":78282,"kind":"person","name":"Stultz Katherine V","position":1,"cik":"0001864500","reported_name":"Stultz Katherine V","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T19:01:02.000Z","date":"2021-03-17","kind":"grant","acquired":true,"shares":209846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction occurred prior to the IPO and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":209846,"derivative":{"exercise_price":6.11,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":209846},"source":{"system":"sec-edgar","filing":"0000899243-21-027015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864500/000089924321027015/doc4.xml","form_type":"4"}},{"id":2648087,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":78282,"kind":"person","name":"Stultz Katherine V","position":1,"cik":"0001864500","reported_name":"Stultz Katherine V","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Series B Preferred Stock","published_at":"2021-07-01T19:01:02.000Z","date":"2021-03-11","kind":"grant","acquired":true,"shares":19763,"price":5.06,"value":100000.78,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction occurred prior to the IPO and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":19763,"derivative":{"underlying":"Common Stock","underlying_shares":8126},"source":{"system":"sec-edgar","filing":"0000899243-21-027015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864500/000089924321027015/doc4.xml","form_type":"4"}},{"id":2648086,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":78282,"kind":"person","name":"Stultz Katherine V","position":1,"cik":"0001864500","reported_name":"Stultz Katherine V","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T19:01:02.000Z","date":"2021-01-13","kind":"grant","acquired":true,"shares":99753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction occurred prior to the IPO and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after August 31, 2020,  and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":99753,"derivative":{"exercise_price":0.3,"expiration_date":"2031-01-12","underlying":"Common Stock","underlying_shares":99753},"source":{"system":"sec-edgar","filing":"0000899243-21-027015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864500/000089924321027015/doc4.xml","form_type":"4"}},{"id":2648085,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":78282,"kind":"person","name":"Stultz Katherine V","position":1,"cik":"0001864500","reported_name":"Stultz Katherine V","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Common Stock","published_at":"2021-07-01T19:01:02.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":8126,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":216020,"source":{"system":"sec-edgar","filing":"0000899243-21-027015","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864500/000089924321027015/doc4.xml","form_type":"4"}}]}